Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 383,928	$ 90,326
Accounts receivable, net of reserves of $6,784 in 2020 and $3,581 in 2019	331,429	269,312
Inventories	209,873	195,019
Other current assets	137,508	124,982
Total current assets	1,062,738	679,639
Long-Term Assets:
Property and equipment, net	555,167	533,845
Operating lease right-of-use assets	91,171	80,607
Goodwill	243,347	239,724
Intangible assets, net	52,543	58,468
Other long-term assets	289,595	240,192
Total long-term assets	1,231,823	1,152,836
TOTAL ASSETS	2,294,561	1,832,475
Current Liabilities:
Accounts payable	74,558	72,172
Accrued liabilities	415,648	322,938
Line of credit	0	288,765
Current portion of long-term debt	49,988	0
Current portion of deferred revenue	42,567	41,462
Total current liabilities	582,761	725,337
Long-Term Liabilities:
Deferred income tax liabilities	11,707	33,024
Long-term debt, net of current portion	858,492	698,910
Long-term deferred revenue, net of current portion	46,163	48,743
Long-term operating lease liabilities	77,039	67,472
Other long-term liabilities	85,604	81,164
Total long-term liabilities	1,079,005	929,313
Total liabilities	1,661,766	1,654,650
Commitments and Contingencies (Note 16)
Stockholders’ Equity:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 106,457 shares in 2020 and 105,711 shares in 2019; Outstanding: 85,449 shares in 2020 and 85,471 shares in 2019	10,646	10,571
Additional paid-in capital	1,294,849	1,213,517
Deferred stock units: Outstanding: 87 units in 2020 and 143 units in 2019	4,503	4,462
Retained earnings	2,175,595	1,595,648
Accumulated other comprehensive loss	(53,615)	(46,182)
Treasury stock, at cost: 21,008 shares in 2020 and 20,240 shares in 2019	(2,799,890)	(2,600,543)
Total IDEXX Laboratories, Inc. stockholders’ equity	632,088	177,473
Noncontrolling interest	707	352
Total stockholders’ equity	632,795	177,825
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 2,294,561	$ 1,832,475